Sublingual Tablet for Postoperative Pain

"The primary assessment of this trial's success is the participants' Postoperative Pain Scores in the post-anesthesia care unit, measured over a 24 hour period. Other metrics include the Sedation level on PACU (measured from 0 to 10), Inpatient Floor Pain scores (assessed via NRS scale), and Length of stay in PACU until discharge for transfer."

"An individual's eligibility for this clinical trial hinges on the fact that they must be in a state of postoperative pain and between 18-85 years old. This research is currently accepting a maximum of 30 participants."

"Recruitment for this study has been suspended. The trial was published on December 1st, 2020 and the last update took place November 21st of 2022. Currently there are 618 studies actively looking for volunteers with pain or postoperative issues as well as 17 trials involving Sublingual Tablets that require participants."

"The trial's listing on clinicaltrials.gov verifies that patient recruitment has been suspended for this particular medical investigation; the study was first posted in December 1st 2020, and last amended November 21st 2022. However, 635 other trials are actively seeking patients at present."

"Currently, 17 clinical trials for Sublingual Tablet are underway with 5 of these trials in Phase 3. Additionally, 25 medical centres worldwide are conducting studies on the tablet form medication, among them being several sites located in Wuhan, Hubei."

"Traditionally, the sublingual tablet is utilized to manage pain. However, it can also be prescribed for general anesthesia and short-term opioid analgesia; plus, this medication may also be applied during intubation procedures."

"There is a plethora of evidence backing the safety profile of Sublingual Tablet and thus, it was given a score of 3."

"To be eligible for this clinical trial, patients must fall within the age range of 18 and 85. Additionally, 84 trials are available for those under 18 years old and 500 studies exist for people older than 65."